Drug Profile
KP 692
Alternative Names: FFC 14a; KP 1019; NSC 666158Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Heidelberg
- Developer Faustus Forschungs Compagnie; University of Heidelberg
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
- Discontinued Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Austria (IV-infusion)
- 29 May 2009 Phase I development is ongoing
- 01 Dec 2005 Phase-I clinical trials in Solid tumours in Austria (IV-infusion)